Given the strong data to support the use of statins and other proven therapies for dyslipidemia (ezetimibe, PCSK9 inhibition, bempedoic acid and icosapent ethyl) for ASCVD risk reduction, a clinician-patient discussion should always evaluate for the use of dietary supplements and help guide our patients to what we know works. This evidence concerns the gene PCSK9 and atherosclerosis.